Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
Jiangsu Hengrui Pharmaceuticals has signed a major licensing agreement, granting GlaxoSmithKline (GSK) worldwide rights to its HRS-9821 drug and 11 additional programs for an upfront payment of $500 million. If all development and sales milestones are reached, Hengrui could receive as much as $12 billion in total.
HRS-9821 is currently in development for chronic obstructive pulmonary disease (COPD), while the other assets span early-stage projects in oncology, respiratory, immunology, and inflammation. News of the deal sent Hengrui’s Shanghai-listed shares up 6.6% and its Hong Kong shares soaring 8.5%, far outperforming local indices.
This blockbuster partnership highlights the increasing global footprint of Chinese pharmaceutical innovation and brings Hengrui one step closer to international markets.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-28
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
Recommend Reading
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
Costs Weaken Significantly, PTA Price Center of Gravity Shifts Lower
-
Kemira to Expand Drinking Water Treatment Portfolio with New ACH Production Line
-
Costs Weaken Significantly, Center of Gravity for Polyester Staple Fiber Prices Shifts Lower
-
ECHEMI High Quality Inquiries (21-25 Jul)
-
Premium Global Chemical Sourcing Requests (18-21Jun, 2026)